CDK4 and cancer: The effect of the drug on other types of cancer, as well as the results obtained in this work, support the hypothesis put forward by the present researchers that this drug will join CDK4/6 and FABP6 protein products (specifically in carcinogenic tissue due to its low expression in different tissues), inhibiting both functions and therefore significantly reducing the development of cancer.